Dissecting the role of insulin resistance in the metabolic syndrome

Current Opinion in Lipidology

Volumn 20, Issue 3, 2009, Pages 206-210

  Haas, Joel T ^a   Biddinger, Sudha B ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

Author keywords

Cholesterol gallstones; Dyslipidemia; Forkhead box O1; Hepatic fatty acid metabolism; Sterol regulatory element binding protein 1c

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR O1; INSULIN RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CHOLESTEROL STONE; FATTY LIVER; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; INSULIN; METABOLIC SYNDROME X; SIGNAL TRANSDUCTION;

EID: 67049155945     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832b2024     Document Type: Review

References (51)

1. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291:2847-2850.
2. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33:283-303.
3. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
4. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal - joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289-2304.
5. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 2006; 68:123-158.
6. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phos-phorylating and inhibiting aforkhead transcription factor. Cell 1999; 96:857-868.
7. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117:421-426.
8. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeo-genesis through FOX01-PGC-1 alpha interaction. Nature 2003; 423:550-555.
9. Li X, Monks B, Ge Q, Birnbaum MJ. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1 alpha transcription coactivator. Nature 2007; 447:1012-1016.
10. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002; 366:377-391.
11. Kodama S, Koike C, Negishi M, Yamamoto Y. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 2004; 24:7931-7940.
12. Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 2006; 281:10105-10117.
13. Samuel VT, Choi CS, Phillips TG, et al. Targeting foxol in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 2006; 55:2042-2050.
14. Altomonte J, Richter A, Harbaran S, et al. Inhibition of Foxol function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab 2003; 285:E718-E728.
15. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003; 44:22-32.
16. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008; 118:2347-2364. This study establishes Mttp as a FoxO1 target.
17. Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008; 14:778-782. This study defines the mechanisms by which hepatic insulin resistance increases the susceptibility to cholesterol gallstones.
18. Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem 2003; 278:48275-48282.
19. Yu L, Gupta S, Xu F, et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem 2005; 280:8742-8747.
20. Shimano H, Shimomura I, Hammer RE, et al. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 1997; 100:2115-2124.
21. Matsumoto M, Ogawa W, Teshigawara K, et al. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 2002; 51:1672-1680.
22. Dong XC, Copps KD, Guo S, et al. Inactivation of hepatic Foxol by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008; 8:65-76. This study shows the important role played by FoxO1 in mediating the effects of insulin resistance on glucose homeostasis.
23. Taniguchi CM, Kondo T, Sajan M, et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCIambda/zeta. Cell Metab 2006; 3:343-353.
24. Matsumoto M, Ogawa W, Akimoto K, et al. PKCIambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 2003; 112:935-944.
25. Porstmann T, Griffiths B, Chung YL, et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005; 24:6465-6481.
26. Ono H, Shimano H, Katagiri H, et al. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 2003; 52:2905-2913.
27. Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14:2819-2830.
28. Yabe D, Komuro R, Liang G, et al. Liver-specific mRNA for lnsig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc Natl Acad Sci USA 2003; 100:3155-3160.
29. Kotzka J, Muller-Wieland D, Koponen A, et al. ADD1/SREBP-1c mediates insulin-induced gene expression linked to the MAP kinase pathway. Biochem Biophys Res Commun 1998; 249:375-379.
30. Kim KH, Song MJ, Yoo El, et al. Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c. J Biol Chem 2004; 279: 51999-52006.
31. Sundqvist A, Bengoechea-Alonso MT, Ye X, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 2005; 1:379-391.
32. Shimano H, Horton JD, Shimomura I, et al. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1 a in livers of transgenic mice and in cultured cells. J Clin Invest 1997; 99:846-854.
33. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125-1131.
34. Liang G, Yang J, Horton JD, et al. Diminished hepatic response to fasting/ refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1 c. J Biol Chem 2002; 277:9520-9528.
35. Yahagi N, Shimano H, Hasty AH, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002; 277:19353-19357.
36. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6:87-97.
37. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 2003; 111:463-468.
38. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008; 7:125-134. This study defines the mechanisms by which hepatic insulin resistance may contribute to dyslipidemia and atherosclerosis.
39. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1994; 1215:9-32.
40. Fisher EA, Pan M, Chen X, et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 2001; 276:27855-27863.
41. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439:484-489.
42. Shaffer EA, Small DM. Biliary lipid secretion in cholesterol gallstone disease. The effect of cholecystectomy and obesity. J Clin Invest 1977; 59:828-840.
43. Bennion U, Grundy SM. Effects of obesity and caloric intake on biliary lipid metabolism in man. J Clin Invest 1975; 56:996-1011.
44. Kubota N, Kubota T, Itoh S, et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 2008; 8:49-64. This article provides compelling data that insulin signals primarily through Irs1 in the fed state but through Irs2 in the fasted state. This suggests that these two proteins, which have largely been considered redundant, may in fact have distinct roles in insulin signaling.
45. Biddinger SB, Almind K, Miyazaki M, et al. Effects of diet and genetic background on sterol regulatory element-binding protein-1 c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes 2005;54:1314-1323.
46. Semple RK, Sleigh A, Murgatroyd PR, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119:315-322. This important study on humans characterizes the effects of mutations in the insulin receptor and its downstream target, AKT2, on serum and hepatic triglyceride levels.
47. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008; 7:95-96.
48. Jump DB, Botolin D, Wang Y, et al. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135:2503-2506.
49. Matsuzaka T, Shimano H, Yahagi N, et al. Insulin-independent induction of sterol regulatory element-binding protein-1 c expression in the livers of strep-tozotocin-treated mice. Diabetes 2004; 53:560-569.
50. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115:1298-1305.
51. Kakuma T, Lee Y, Higa M, et al. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A 2000; 97:8536-8541.